Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials
Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS…